Approximately 86% achieve at least 5% reduction, 69% achieve 10% or more, and 51% achieve 15% or more
[1] [2] The severity of an overdose depends on several factors: The amount taken beyond the prescribed dose Individual patient characteristics (weight, concurrent medications) Timing of the last dose and whether other diabetes medications are being used Current blood glucose levels and recent food intake Gastrointestinal symptoms typically intensify with higher doses, as semaglutide's effect on gastric motility becomes more pronounced
In the STEP 1 trial the largest placebo-controlled study of semaglutide for weight management participants taking 2.4 mg of semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group
Its always better to ask than to risk using a dose that might not work as well as it should
Date: September 21, 2025 Source: Duke University Summary: Duke University scientists have discovered that pancreatic alpha cells, long believed to only produce glucagon, actually generate powerful amounts of GLP-1 the same hormone mimicked by popular diabetes drugs like semaglutide (Ozempic and Wegovy)
